Ivonescimab for Advanced Leiomyosarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new immunotherapy drug called ivonescimab in people with leiomyosarcoma (a rare soft-tissue cancer) that cannot be surgically removed or has spread. The drug works by helping your immune system recognize and fight cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with leiomyosarcoma that cannot be surgically removed or has spread to other parts of your body
- You have received 1–3 prior cancer treatments (but not certain specific drugs like pazopanib, cabozantinib, sunitinib, or immune checkpoint inhibitors)
- Your overall health and organ function (blood counts, kidney, liver, heart) meet minimum standards
- You have adequate tumor tissue available for research or agree to an optional biopsy
- You are willing to use effective contraception for 90 days after treatment ends (if of childbearing potential)
- You have no active autoimmune disease, HIV with uncontrolled viral load, or hepatitis C
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—all-trans retinoic acid (ATRA, a vitamin A derivative) and cemiplimab (an immunotherapy)—for people with advanced leiomyosarcoma who've already had chemotherapy. The goal is to see if this combination can shrink tumors or slow cancer growth.
This Phase 2 study tests a combination of three anti-cancer medicines to shrink or control leiomyosarcoma that cannot be fully removed by surgery or has spread. It may help people whose cancer has grown after prior treatment.
This trial tests a new immune cell therapy (MASCT-I) combined with standard chemotherapy (doxorubicin and ifosfamide) for people with advanced soft tissue sarcoma who have not had prior chemotherapy or targeted therapy. The goal is to see if the combination works better than chemo alone.
This study tests a new drug called ivonescimab for people with advanced endometrial or cervical cancer that has progressed after standard platinum-based chemotherapy. Ivonescimab is an investigational immunotherapy that may help your immune system fight the cancer.
This trial tests a new drug called ivonescimab for people with advanced skin angiosarcoma that has spread or cannot be removed by surgery. You must have already tried a chemotherapy drug like paclitaxel or docetaxel. The goal is to see if ivonescimab can help shrink or slow the cancer.
This trial uses your tumor's lab-grown organoids to find the most effective personalized treatment for advanced leiomyosarcoma. It aims to match you with a drug that targets your specific cancer.
Hear when a new Leiomyosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.